Wynzora (Calcipotriene and Betamethasone dipropionate) for Psoriasis

Overview
Wynzora is a prescription drug approved by the U.S. Food and Drug Administration (FDA) to treat plaque psoriasis in people ages 18 and older. Wynzora is a combination drug composed of Calcipotriene and Betamethasone dipropionate.

Betamethasone dipropionate is a high-potency corticosteroid. It is believed that Betamethasone dipropionate works in cases of psoriasis by suppressing immune system activity. Calcipotriene is a vitamin D analog. It is believed that Calcipotriene works in cases of psoriasis by regulating skin cell growth.

How do I take it?
Wynzora is applied topically to the affected areas in the form of a lotion once a week for eight weeks.

Side effects
The FDA-approved label for Wynzora lists common side effects including irritation at the application site, upper respiratory infection, and headache.

Rare but serious side effects listed for Wynzora can include fetal harm in pregnant women and vision problems, including an increased chance of developing cataracts and glaucoma. Wynzora can cause problems with metabolism, such as the development of Cushing’s syndrome and reversible hypothalamopituitary-adrenal (HPA) axis suppression.

For more details about this treatment, visit:
Wynzora — MC2 Therapeutics

www.wynzora.com